Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257959 | 1.00 | MME (0.74) | MMEAGTR1 | |
| SCHEMBL1258999 | 0.93 | MME (0.84) | MMEAGTR1 | |
| SCHEMBL1258996 | 0.93 | MME (0.84) | MMEAGTR1 | |
| SCHEMBL1255192 | 0.92 | MME (0.88) | MMEAGTR1 | |
| SCHEMBL1257961 | 0.87 | AGTR1 (0.67) | MMEAGTR1 | |
| SCHEMBL1257712 | 0.84 | AGTR1 (0.66) | MMEAGTR1 | |
| SCHEMBL1257715 | 0.84 | AGTR1 (0.66) | MMEAGTR1 | |
| SCHEMBL1256439 | 0.83 | MME (0.83) | MMEAGTR1 | |
| SCHEMBL2281919 | 0.82 | AGTR2 (0.60) | MMEAGTR1 | |
| SCHEMBL2281910 | 0.82 | AGTR2 (0.60) | MMEAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150065543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-05 | — | — | US | disclosed |
| US-8664254-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130245087-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-09-19 | — | — | US | disclosed |
| US-8013005-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7879896-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | THERAVANCE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | AGTR2, REN, AGTR1 | MME 4/4885AGTR1 3/4885 |
| US-20130245087-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 13/4885AGTR1 1/4885 |
| US-20150065543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 5/4885AGTR1 1/4885 |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | AGTR1, AGTR2, REN | MME 13/4885AGTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.